This report was first published by Endpoints News. To see the original version, click here
The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies.
A new San Diego biotech called cAMPfield Therapeutics is the latest to secure backing from some of the most well-known and deep-pocketed investors in the life sciences.
您已阅读12%（404字），剩余88%（3078字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。